This systematic review and meta-analysis of randomized controlled trials suggests that treatment with Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) is unlikely to reduce or increase cancer incidence or mortality.
- The review included RCTs that compared SGLT2 inhibitors or SGLT1/2 inhibitors to placebo, active interventions, or no intervention in adults (aged ≥ 18 years), with a minimum follow-up of 48 weeks and that reported at least 1 case of cancer or 1 death due to cancer.
- Treatment with SGLT2 inhibitors did not reduce or increase cancer incidence or mortality.
- Similarly, the risk of bladder, breast, and renal cancers (malignancies of special safety concern), the most common malignancies or other site-specific cancers were not different in adults treated with SGLT2 inhibitors from the risk of those treated with control interventions.
- "Similar to our results, a Scandinavian cohort study did not find an increase in the risk of bladder and renal cancers comparing SGLT2 inhibitors to glucagon-like peptide-1 receptor agonists treatment"
Ref:
doi.org/10.2337/dc21-1…
Ref:
doi.org/10.2337/dc21-1…
Sodium-Glucose Cotransporter-2 inhibitors and Cancer Outcomes: a systematic review and meta-analysis of randomized controlled trials
doi.org/10.1016/j.diab…
#MetabolicSyndrome #InsulinResistance #Diabetes #Cancer
doi.org/10.1016/j.diab…
#MetabolicSyndrome #InsulinResistance #Diabetes #Cancer
• • •
Missing some Tweet in this thread? You can try to
force a refresh
